QGEN - QIAGEN N.V.
| Previous Close | 34.56 |
| Open | 34.54 |
| Bid | 33.00 x 1000 |
| Ask | 34.39 x 900 |
| Day's Range | 34.24 - 34.81 |
| 52 Week Range | 32.33 - 41.55 |
| Volume | 785,511 |
| Avg. Volume | 880,792 |
| Market Cap | 7.768B |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | 40.83 |
| EPS (TTM) | 0.84 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.00 |
- Zacks
Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.
- Business Wire
QIAGEN’s New QIAstat-Dx Gastrointestinal Panel Demonstrates Excellent Performance in Multicenter Clinical Study in Europe
Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis. The QIAstat-Dx Gastrointestinal Panel delivered high performance compared to other, existing multiplex tests in this study which evaluated 385 patient samples at university hospital laboratories across Europe. Multiple pathogens were identified in nearly one-third of the patient samples that tested positive.
- Zacks
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
- Simply Wall St.
QIAGEN N.V. (NYSE:QGEN) Insiders Have Been Selling
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Thomson Reuters StreetEvents
Edited Transcript of QGEN earnings conference call or presentation 31-Jul-19 1:00pm GMT
Q2 2019 Qiagen NV Earnings Call
- GuruFocus.com
Bank of Italy Buys Qiagen NV, Sells Ferrari NV
Rome, L6, based Investment company Bank of Italy (Current Portfolio) buys Qiagen NV, sells Ferrari NV during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Bank of Italy. Continue reading...
Motley FoolQiagen NV (QGEN) Q2 2019 Earnings Call Transcript
QGEN earnings call for the period ending June 30, 2019.
- Zacks
QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View
QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.
- Business Wire
QIAGEN reports full results for second quarter and first half of 2019
QIAGEN reports full results for second quarter and first half of 2019
- Zacks
Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
QIAGEN Reports Results for Second Quarter of 2019; Updates Full-Year 2019 Outlook Due to Decision to Restructure China NGS Partnership
QIAGEN N.V. today announced results of operations for the second quarter of 2019, achieving the outlook set for net sales growth and adjusted earnings per share at constant exchange rates .
- Zacks
Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Don't Sell QIAGEN N.V. (NYSE:QGEN) Before You Read This
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- Business Wire
QIAGEN N.V. to Report Second Quarter and First Half of 2019 Results
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter and first half of 2019 on Tuesday, July 30 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
- Motley Fool
Here's Why NeoGenomics Stock Rose 74% in the First Half of the Year
The genetic testing leader continues to set new quarterly revenue records.
- Zacks
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
- Simply Wall St.
What Should Investors Know About The Future Of QIAGEN N.V.'s (NYSE:QGEN)?
After QIAGEN N.V.'s (NYSE:QGEN) earnings announcement in March 2019, analysts seem fairly confident, as a 19% increase...
- Zacks
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
- Business Wire
QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and Interpreted
Industry-leading bioinformatics software delivers genomic insights for precision medicine
- Zacks
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
- Business Wire
QIAGEN and McKesson Agree to Distribute QIAstat-Dx Syndromic Testing Solution to Smaller Hospitals and Other Select Segments in the United States
Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation , a global leader in healthcare supply chain management solutions, to serve as the exclusive distributor of QIAGEN’s QIAstat-Dx syndromic testing solution in the “acute” market segment of U.S. hospitals with 200 beds or less and in other select segments. The agreement also makes McKesson a non-exclusive distributor for future expansion of QIAstat-Dx into the non-acute retail clinics located in U.S. retail pharmacies.
- Simply Wall St.
Is QIAGEN N.V. (NYSE:QGEN) Overpaying Its CEO?
Peer Schatz has been the CEO of QIAGEN N.V. (NYSE:QGEN) since 2004. This analysis aims first to contrast CEO...
